Showing results (811-820 of 828) with videos related to

Sort By:
Pageof 83
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
Frontiers in Physiology|April 1, 2022
Effects of High-Volume Versus High-Load Resistance Training on Skeletal Muscle Growth and Molecular AdaptationsChristopher G Vann, Casey L Sexton, Shelby C Osburn, et al.
Physical Review Letters|September 11, 2020
ΔK=0 M1 Excitation Strength of the Well-Deformed Nucleus ^{164}Dy from K MixingT Beck, V Werner, N Pietralla, et al.
The Netherlands Journal of Medicine|December 22, 2015
Trends in practice of blood glucose control in critically ill patients in the NetherlandsR T M van Hooijdonk, S Eslami, N F de Keizer, et al.
Infection and Immunity|June 24, 2004
Description of the transcriptomes of immune response-activated hemocytes from the mosquito vectors Aedes aegypti and Armigeres subalbatusLyric C Bartholomay, Wen-Long Cho, Thomas A Rocheleau, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|January 12, 2026
Limited effects of dietary nitrate supplementation with resistance training on skeletal muscle and vascular outcomes and in middle-aged and older adultsMason C McIntosh, Breanna J Mueller, Dakota R Tiede, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 5, 1997
The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux DiseaseI T Beck, M C Champion, S Lemire, et al.
Cancer Research|July 1, 1996
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendationsW T Beck, T M Grogan, C L Willman, et al.
Physical Review Letters|May 1, 2026
Collapse of Nuclear Collectivity along the N=Z LineM A Bentley, R Taniuchi, R Wadsworth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ M Weiss, T Csoszi, M Maglakelidze, et al.
Pageof 83